| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 375000.0 | 500000.0 | 2635094.0 |
| Other income | 0.0 | 0.0 | 676.0 |
| Total income | 375000.0 | 500000.0 | 2635770.0 |
| Profit before exceptional items & tax | 15624.0 | 105206.0 | 18548.0 |
| Profit before tax | 15624.0 | 105206.0 | 18548.0 |
| Net profit | -81745.0 | 105206.0 | -834895.0 |
| Operating margin | 4.2% | 21.0% | 0.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | -85.80% |
|---|
BSE results filing, NSE: GVBL. Figures extracted from the filing.
Genomic Valley Biotech Ltd: key numbers
- Share price
- ₹32.24
- Market cap
- ₹9.85 Cr
- Revenue (annual)
- ₹0.27 Cr
- Net profit (annual)
- ₹0.03 Cr
- P/E (TTM)
- 484.2×Sector 47.3×
- Promoter holding
- 46.06%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Genomic Valley Biotech Ltd
All →Genomic Valley Biotech Other Announcement
Genomic Valley Biotech Limited received approval from the Registrar of Companies to extend the AGM deadline for FY26 to 31st December 2026. This is a regulatory compliance update.
Genomic Valley Biotech Q1 FY27 Results: Net Profit ₹146,162 Cr, Down 40.7% YoY
Genomic Valley Biotech Ltd reported revenue from operations of ₹380,000 Cr (-57.8% YoY) and net profit of ₹146,162 Cr (-40.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹146,162 Cr · -40.7% YoY
Genomic Valley Biotech Board Meeting Date
Genomic Valley Biotech Limited has scheduled a Board Meeting for August 14, 2026. The board will consider and approve unaudited standalone financial results for the June quarter.
Genomic Valley Biotech Financial Results
Genomic Valley Biotech approved FY26 audited results, reporting a total revenue of ₹0.27 Crore. The company also appointed Mr. Navjyoti Kumar Jha as Internal Auditor.
- Value
- ₹0.27 Cr
Genomic Valley Biotech Board Meeting Date
Genomic Valley Biotech scheduled a board meeting on May 29, 2026, to approve audited annual financial results. The trading window remains closed until May 31.
Genomic Valley Biotech Other Announcement
Genomic Valley Biotech Ltd's promoter, Yogesh Agrawal, declared that the promoter group made no direct or indirect encumbrances on their shareholding during FY 2025-26. This disclosure complies with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.